Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 1946 • ACR Convergence 2022
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Jonathan Li¹, Emily Mirizio², Katherine Buhler³, Anne Stevens⁴, May Choi⁵, Kaila Schollaert-Fitch², Kathryn Torok², Christopher Liu² and Marvin Fritzler³, ¹Combined Internal Medicine-Pediatrics Residency Program, Children's Hospital of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ³University of Calgary, Calgary, AB, Canada, ⁴Janssen, Hansville, WA, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral…
Abstract Number: 2155 • ACR Convergence 2022
Sclerodermoid Reaction Following Immune Checkpoint Inhibitor Therapy: A Case Series from MD Anderson Cancer Center
Julia Chernis¹ and Maryam Buni², ¹McGovern Medical School at the UTHSC Houston, Houston, TX, ²MD Anderson Cancer Center, Bellaire, TX
Background/Purpose: Immune checkpoint inhibitors (ICIs) have proven to be efficacious in the treatment of multiple malignancies.[1] they are associated immunologic activation has been implicated in…
Abstract Number: 2156 • ACR Convergence 2022
Clinical Benefits of Lung Transplantation in Systemic Sclerosis-related Interstitial Lung Disease; A Single-Center Retrospective Study
Yoichi Nakayama¹, Ran Nakashima¹, Tomohiro Handa², Kiminobu Tanizawa², Akihiro Ohsumi³, Mirei Shirakashi¹, Ryosuke Hiwa¹, Hideaki Tsuji¹, Koji Kitagori¹, Shuji Akizuki⁴, Hajime Yoshifuji⁵, Hiroshi date³ and Akio Morinobu⁵, ¹Kyoto University Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Kyoto, Japan, ²Kyoto University Graduate School of Medicine, Department of Respiratory Medicine, Kyoto, Japan, ³Kyoto University Graduate School of Medicine, Department of Thoracic Surgery, Kyoto, Japan, ⁴Kyoto universtiy hospital, Kyoto City, Japan, ⁵Kyoto University, Kyoto, Japan
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with microangiopathy and fibrosis affecting the skin and visceral organs. Interstitial lung disease (ILD) is a…
Abstract Number: 0435 • ACR Convergence 2022
Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
deborah Eshagh¹, Thomas Quéméneur², Alexandre Karras³, Viviane Queyrel⁴, Jean Francois Augusto⁵, Christian Agard⁶, Vincent Audard⁷, Marion Couderc⁸, PIerre Duffau⁹, Cecile-Audrey Durel¹⁰, Stan Faguer¹¹, Noemie Jourde Chiche¹², Aurelie Lavergne¹³, Christian Lavigne⁵, Nicolas Limal¹, Amélie Servettaz¹⁴, Perrine Smets¹⁵, Alexis Regent¹⁶, Luc Mouthon¹⁶ and Benjamin Terrier¹⁶, ¹APHP, Paris, France, ²Valenciennes Hospital, Valenciennes, France, ³HEGP, Paris, France, ⁴CHU NIce, Nice, France, ⁵CHU Angers, Angers, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷CHU Henri Mondor, Creteil, France, ⁸University Hospital, Clermont-Ferrand, France, ⁹CHU Bordeaux, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹CHU Toulouse, Toulouse, France, ¹²APHM, Marseille, France, ¹³CHU Rennes, Rennes, France, ¹⁴CHU Reims, Reims, France, ¹⁵CHU Clermont Ferrand, Clermont-Ferrand, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by autoantibody production, skin and visceral fibrosis, and vasculopathy. The onset of ANCA-associated vasculitides (AAV)…
Abstract Number: 2160 • ACR Convergence 2022
The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
Henriette Didriksen¹, Øyvind Molberg², Adi Mehta³, Suzana Jordan⁴, Håvard Fretheim³, Einar Gude³, Thor Ueland³, Cathrine Brunborg³, Vyacheslav Palchevskiy⁵, Torhild Garen³, Øyvind Midtvedt³, Arne Andreassen³, Fridtjof Lund-Johansen³, Oliver Distler⁴, John Belperio⁵ and Anna-Maria Hoffmann-Vold³, ¹Oslo University Hospital, Moss, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
Abstract Number: 0405 • ACR Convergence 2021
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Hao Cheng Shen¹, Catherine Faucher², Anne Chin³, Carl Chartrand-Lefebvre³, Ragui Chehata⁴, Julia Cadrin-Tourigny⁵, Francois-Pierre Mongeon⁶, Jean-Paul Makhzoum⁷, Océane Landon-Cardinal⁸, Josiane Bourré-Tessier⁸, Éric Rich⁹, Jean-Richard Goulet⁸, Paul R Fortin¹⁰, Jean-Luc Senécal⁸ and Sabrina Hoa⁸, ¹Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Department of Medicine, Université Laval, Québec, QC, Canada, ³Department of Radiology, Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Université de Montréal, Montreal, Montréal, QC, Canada, ⁵Division of Non-Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Division of electrophysiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁷Division of Internal Medicine, Hôpital Sacré-Coeur de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁸Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Centre hospitalier de l’Université de Québec-Université Laval, Montréal, QC, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Cardiac involvement is a leading cause of death in systemic sclerosis (SSc). Cardiac MRI (CMR) is useful in the early assessment of cardiac disease.…
Abstract Number: 1369 • ACR Convergence 2021
Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial
Martín Iglesias¹, Iván Torre-Villalvazo¹, Armando Tovar-Palacio¹, Alejandro Zentella-Dehesa¹, Patricia Butrón-Gandarillas¹, Marta Durand-Carbajal¹, Erik Torre-Anaya², Martha Guevara² and Tatiana Rodriguez-Reyna², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Adipose tissue-derived Stromal Vascular Fraction (ADSVF) has been proposed as regenerative treatment for hand deformities and digital ulcer healing in patients with Systemic Sclerosis…
Abstract Number: 0408 • ACR Convergence 2021
A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography
COSIMO BRUNI¹, Alexandru Garaiman², Lorenzo Tofani³, Suzana Jordan⁴, Carmen-Marina Mihai⁴, Rucsandra Dobrota⁴, Muriel ELHAI⁵, Mike Oliver Becker⁴, Marco Matucci-Cerinic³ and Oliver Distler⁶, ¹University of Florence, Department of Rheumatology, Florence, Italy & Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Florence, Italy, ²University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³University of Florence, Florence, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: High resolution computed tomography (conventional CT) represents the diagnostic gold standard for systemic sclerosis-related interstitial lung disease (SSc-ILD). A low-dose 9-slices (reduced) CT protocol…
Abstract Number: 1376 • ACR Convergence 2021
Outcome Reporting in Systemic Sclerosis-Related Digital Ulcers: A Scoping Review
Michael Hughes¹, Nancy Maltez², Edith Brown³, Virginia Hickey⁴, Heiyoung Park⁵, Beverley Shea², John Pauling⁶, Susanna Proudman⁷, Peter Merkel⁸ and Ariane Herrick⁹, ¹Tameside and Glossop Integrated NHS Foundation Trust, Manchester, United Kingdom, ²University of Ottawa, Ottawa, ON, Canada, ³n/a, Manchester, United Kingdom, ⁴n/a, Adelaide, Australia, ⁵5. National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷University of Adelaide, Medindie, Australia, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Manchester, Salford, United Kingdom
Background/Purpose: Digital ulcers (DUs) are a major cause of pain and disability in patients with systemic sclerosis (SSc). Despite the availability of a range of…
Abstract Number: 0411 • ACR Convergence 2021
Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata² and Shinichi Sato², ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: The exact role of interleukin-17 in systemic sclerosis (SSc) has not been established. This trial assessed the pharmacokinetics (PK), safety, and efficacy of multiple…
Abstract Number: 1377 • ACR Convergence 2021
Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies
Karen Kruzer¹, Roberta G Marangoni¹, Ilana Heckler², Aya Elhage², Varga John³, Monique Hinchcliff⁴, Mary Carns⁵, Kathleen Aren⁵, Amy Wielgosz¹, Marc Nuzzo⁶, Iswariya Venkataraman² and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²EUROIMMUN US, Mountain Lakes, NJ, ³University of Michigan, Ann Arbor, MI, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic sclerosis (SSc) is a clinically heterogenous disease typically characterized by a positive ANA (ANA+), and prototypical antibodies including anti-centromere, anti-topoisomerase, and anti-RNA polymerase…
Abstract Number: 0413 • ACR Convergence 2021
Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials…
Abstract Number: 1379 • ACR Convergence 2021
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Anniek Van Roon², Caroline Roozendaal¹, Andries Smit², Alja J. Stel², Harry Van Goor², Tji-Joong Gan¹, Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
Abstract Number: 0500 • ACR Convergence 2021
Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
Monica Yang¹, Vivien Goh², Monica Espinoza³, Yiwei Yuan⁴, Julia Lee⁵, Mary Carns⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield⁹ and Monique Hinchcliff¹⁰, ¹University of California San Francisco, San Francisco, CA, ²Northwestern University, Chicago, IL, ³Geisel School of Medicine, Hanover, NH, ⁴Dartmouth College, Hanover, NH, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹Geisel School of Medicine, Lebanon, NH, ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Although two subsets in systemic sclerosis (SSc) have been identified based on degree of skin disease, the current classification system, limited vs. diffuse cutaneous,…
Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Murray Baron² and Marie Hudson³, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Jewish General Hospital, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].